A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3 Recruiting
440 enrolled
A Study of Daratumumab
Phase 3 Recruiting
500 enrolled
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Phase 2/3 Recruiting
660 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
CERVINO
Phase 3 Recruiting
380 enrolled
MonumenTAL-6
Phase 3 Recruiting
795 enrolled
MK-2870-009
Phase 3 Recruiting
520 enrolled
MK-5684-01A
Phase 1/2 Recruiting
220 enrolled
TroFuse-022
Phase 3 Recruiting
770 enrolled
MajesTEC-7
Phase 3 Recruiting
1,590 enrolled
MOMENTUM
Phase 2 Recruiting
100 enrolled
SUCCESSOR-1
Phase 3 Recruiting
810 enrolled
OMAHA-003
Phase 3 Recruiting
1,310 enrolled
MK-3475-01E
Phase 2 Recruiting
60 enrolled
MK-5684-004
Phase 3 Recruiting
1,314 enrolled
PLYCOM
Phase 1/2 Recruiting
200 enrolled
MagnetisMM-6
Phase 3 Recruiting
1,116 enrolled
MK-3475-06B
Phase 1/2 Recruiting
230 enrolled
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3 Recruiting
228 enrolled
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1/2 Recruiting
130 enrolled
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 Recruiting
246 enrolled
KEYNOTE-365
Phase 1/2 Recruiting
1,200 enrolled
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Phase 1/2 Recruiting
440 enrolled
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Phase 1 Recruiting
125 enrolled
OLYMPIA-4
Phase 3 Recruiting
216 enrolled
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Phase 1 Recruiting
174 enrolled
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Phase 3 Recruiting
492 enrolled
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Phase 2 Recruiting
127 enrolled
MAGNETISMM-5
Phase 3 Recruiting
944 enrolled
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2 Recruiting
62 enrolled
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Phase 3 Recruiting
292 enrolled
DREAMM-10
Phase 3 Recruiting
520 enrolled
STOMP
Phase 1/2 Recruiting
300 enrolled
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/2 Recruiting
250 enrolled
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Recruiting
130 enrolled
FUMANBA-03
Phase 3 Recruiting
240 enrolled
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Phase 1/2 Recruiting
24 enrolled